Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort studyReportar como inadecuado




Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

* Corresponding author 1 Centre Hospilalier Lyon-Sud 2 Concord Hospital 3 Saint-Luc University Hospital- UCL- Bruxelles 4 Département d-Hematologie 5 Hospital Son Llatzer 6 CHU Reims 7 LYSARC - The Lymphoma Academic Research Organisation 8 Instituto Português de Oncologia de Lisboa, Francisco Gentil 9 Polyclinique Bordeaux Nord Aquitaine 10 University Hospital Hradec Kralove 11 Service d-hématologie 12 Chulalongkorn University THAILAND 13 CHU Pontchaillou Rennes 14 Pathologie morphologique Département de biologie et pathologie médicales Gustave Roussy 15 Peter MacCallum Cancer Centre 16 University of Melbourne

Abstract : An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1217 patients enrolled in the PRIMA study, 1135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1135 patients, 119 were on statins 10.4% at diagnosis. Adverse events frequencies, event-free survival EFS, time to next lymphoma treatment TTNLT, time to next chemotherapy TTNCT and overall survival OS were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the 2 groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT and OS were similar regardless of the use of statins P=.57, P=.85, P=.30 and P=.43 respectively in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy. This article is protected by copyright. All rights reserved





Autor: Emmanuel Bachy - Jane A. Estell - Eric Neste - Reda Bouabdallah - Joan Bargay - Alain Delmer - Bénédicte Gelas-Dore - Maria Sil

Fuente: https://hal.archives-ouvertes.fr/



DESCARGAR PDF




Documentos relacionados